Louis Garguilo

ARTICLES BY LOUIS

  • 5/15/2020

    The Wuhan coronavirus outbreak has brokered a virulent "value" chain debate around the world, including a global CDMO's CEO situated in Tokyo. 

  • 5/14/2020

    Pfizer’s speaking in real-time – actually forward-looking pronouncements of manufacturing intentions and locations – is refreshing, and should be applauded. Does this represent an industry "shift"?

  • 5/11/2020

    The CDMO market is estimated to grow to $157.7 billion in 2025, a compound annual growth rate (CAGR) of 6.9%, according to an industry report. But what kind of CDMO growth is best for Outsourced Pharma readers?

  • 5/6/2020

    To diversify China-dependent supply chains and procure materials, API and products in the U.S., we'd literally need to start digging.

  • 5/1/2020

    Don Buckner left a comment to my recent '50 By 25" editorial: “Will have success if the buyers demand it.” I liked the idea of buyer-driven demand as a path to explore your supply-chain decisions. It also led to some fundamental questions of your motivations.

  • 4/27/2020

    That’s an unwieldy title for an editorial. But we’ll bundle those three components quickly, thanks to U.S.-based GeoVax Labs CEO David Dodd. He's the quintessential professional to assist readers in assessing and contemplating current and future realities.

  • 4/20/2020

    The questions James E. Brown, President & CEO, DURECT, asked of CDMOs when he founded the company in 1998 remain perfectly operational: "Who are they? Where did those individuals come from? What are their personal track records?”

  • 4/16/2020

    At this time of difficult political, economic, and health-related decision-making, the entire nation needs your practiced mix of data centrality, and your experience in partnerships and (supply-chain) systems where qualitative analysis also play a major role.

  • 4/15/2020

    We featured Sara McCutchan in an earlier editorial, "A Path To Biotech For Young Women." Here she provides strong examples and best practices for small biotechs reliant on outsourcing drug development to CDMOs.

  • 4/8/2020

    The president of a college of pharmacy believes pharmacy graduates should occupy the center of the biopharma drug development and manufacturing industry. In fact, quite a few do already. More are on the way.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.